Baldwidx
I have previously discussed here gene therapies (DNA therapies) and raised specific concerns about the viral vectors that are used for delivering gene therapies, which are meant to be a “one and done” treatment. I’ve also mentioned adverse events that can result from the immunosuppressant drugs that are used prophylactically with viral vector delivered gene therapy.
PYC Therapeutics uses antisense oligonucleotides, which are one type of RNA therapy. Antisense therapies don’t have a permanent effect like gene therapies and typically are dosed every couple of months. PYC is employing peptide conjugation to enhance cellular delivery of its antisense therapies. This allows lower doses that are less likely to cause serious adverse events.
As my grasp of genetic medicine is limited, I've included a PDF link below to an information sheet on the different gene therapy approaches.
https://hotcopper.com.au/threads/competitors-to-daybue.7335954/page-19?post_id=74384394
https://hotcopper.com.au/threads/neurogene-for-rett.7195113/page-7?post_id=65892502
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
Neuren Media and Analyst Coverage, page-1240
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.70 |
Change
-0.310(2.38%) |
Mkt cap ! $1.623B |
Open | High | Low | Value | Volume |
$12.80 | $12.90 | $12.69 | $5.154M | 403.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4631 | $12.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.76 | 1060 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4631 | 12.700 |
5 | 2909 | 12.690 |
6 | 5624 | 12.680 |
2 | 2480 | 12.660 |
2 | 7081 | 12.650 |
Price($) | Vol. | No. |
---|---|---|
12.760 | 1060 | 1 |
12.810 | 1733 | 4 |
12.820 | 2000 | 1 |
12.830 | 1980 | 1 |
12.840 | 1980 | 1 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online